Thank you for claiming your business. Kindly check your Email for verification mail from Sulekha.com Our team will contact you shortly!.
About Seattle Genetics, Inc
Seattle Genetics, co-founded by Clay Siegall, is a biotechnology company leading the field of antibody-drug conjugates (ADCs) for the treatment of cancer. Our technology is designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Our lead program, ADCETRIS® (brentuximab vedotin), is the first in a new class of ADCs. In collaboration with Takeda Pharmaceutical Company Limited, it is approved in more than 60 countries. To further expand the ADCETRIS opportunity, we are conducting a broad clinical development program evaluating its potential to become the foundation of treatment for CD30-expressing lymphomas.
